Delving into the Latest Updates on Lenalidomide with Synapse

Overview

Basic Info

Drug Type

Degradable Molecular Glue

Synonyms

1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CMIO-LLD

+ [18]

Target

CK1α x CRBN x IKZF1 x IKZF3

Action

inhibitors, modulators, degraders

Mechanism

CK1α inhibitors(casein kinase 1 alpha 1 inhibitors), CRBN modulators(Cereblon modulators), IKZF1 degraders(DNA-binding protein Ikaros degraders)

Therapeutic Areas

NeoplasmsImmune System DiseasesCongenital Disorders+ [7]

Active Indication

Large B-cell lymphomaMarginal Zone B-Cell LymphomaAdult T-Cell Leukemia-Lymphoma+ [66]

Inactive Indication

Aase Smith Syndrome 2acute leukemiaAcute Lymphoblastic Leukemia+ [119]

Originator Organization

Celgene Corp.

Active Organization

Incyte Corp.Bristol-Myers Squibb Pharma EEIG

Celgene Corp.

+ [29]

Inactive Organization

Onyx Therapeutics, Inc.Janssen-Cilag International NV

Cephalon, Inc.

+ [9]

License Organization

Xencor, Inc.

MorphoSys AG

Drug Highest PhaseApproved

First Approval Date

United States (27 Dec 2005),

Myelodysplastic Syndromes

RegulationOrphan Drug (United States), Priority Review (China), Special Review Project (China), Orphan Drug (Japan)

Login to view timeline

Structure/Sequence

Molecular FormulaC13H13N3O3

InChIKeyGOTYRUGSSMKFNF-UHFFFAOYSA-N

CAS Registry191732-72-6

This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple myeloma.

Start Date15 Apr 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07029776

/ Not yet recruitingPhase 2IIT

A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)

The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.

Start Date01 Apr 2026

Sponsor / Collaborator

The University of Arkansas

[+1]

NCT06348147

/ SuspendedPhase 2

An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation

This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing.

Start Date01 Jan 2026

Sponsor / Collaborator

Lineberger Comprehensive Cancer Center

100 Clinical Results associated with Lenalidomide

Login to view more data

100 Translational Medicine associated with Lenalidomide

Login to view more data

100 Patents (Medical) associated with Lenalidomide

Login to view more data

8,547

Literatures (Medical) associated with Lenalidomide

31 Dec 2025·Hematology

Review

Author: Kollsete Gjelberg, Hilde ; Dahl Hamnvik, Lars Henrik ; Sefland, Øystein ; Sandnes, Miriam ; Reikvam, Håkon ; Ktoridou-Valen, Irini ; Andersson Tvedt, Tor Henrik ; Brendsdal Forthun, Rakel

OBJECTIVES:

Myeloid neoplasms occurring after cytotoxic therapy (MN-pCT), previously termed therapy-related myelodysplastic neoplasia (MDS) or therapy-related acute myelogenous leukemia (AML), pose significant treatment challenges due to high resistance, poor chemotherapy tolerance, and relapse.

METHODS:

We present a 73-year-old woman with therapy-related AML following treatment for myxofibrosarcoma, characterized by the rare RUNX1::MECOM fusion resulting from a t(3;21)(q26;q22) chromosomal translocation. We also review the current literature regarding cases of this rare translocation.

RESULTS:

The patient, previously treated with chemotherapy and radiotherapy for sarcoma, was diagnosed with pancytopenia and hypoplastic bone marrow with increased blasts. Cytogenetic analysis confirmed RUNX1::MECOM fusion. Furthermore, we discuss the molecular mechanisms underlying MECOM rearrangements, specifically the role of the EVI1 oncogene. AML associated with MECOM rearrangements is associated with poor prognosis and resistance to conventional therapies. While allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potential curative treatment, the high relapse rate limits its efficacy. Recent advancements in understanding the molecular drivers of MECOM-related AML suggest potential therapeutic strategies, including hypomethylating agents and novel combinations such as lenalidomide.

CONCLUSION:

this case and literature review emphasizes the importance of long-term monitoring of cancer survivors treated with cytotoxic therapies, as well as awareness of rare translocations in MN-pCT.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States

Article

Author: Li, Jia ; Mahmoudjafari, Zahra ; Masaquel, Anthony ; Parisé, Hélène ; Bercaw, Eric ; Bognar, Katalin ; Wang, Si-Tien

BACKGROUND:

Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+).

METHODS:

A budget impact model was developed for a hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions, and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated.

RESULTS:

Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and -$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from -$0.0256 to -$0.0108.

CONCLUSIONS:

With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.

31 Dec 2025·Hematology

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis

Review

Author: Lin, Cheng-Hsien ; Teng, Chieh-Lin Jerry ; Su, Yu-Chen ; Wang, Yin-Che

BACKGROUND:

The current study aimed to compare treatment responses, the incidence of the need for auto-HSCT, and the occurrence of specific adverse events (AEs) between VTD and velcade, VRD induction regimens in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM).

METHODS:

This systematic review and meta-analysis included 15 studies: six evaluating the VTD regimen and nine evaluating the VRD one. The primary endpoints were response rates after induction therapy and the incidence of a need for autologous hematopoietic stem cell transplantion (auto-HSCT) between the groups. We also examined the occurrence of grade 3 or 4 hematological, infection, and thrombotic AEs in both groups.

RESULTS:

The VTD group showed an overall response rate (ORR) of 93%, while the VRD group had an ORR of 86%. The very good partial response (VGPR) rates were 61% in the VTD group and 60% in the VRD one. The auto-HSCT rate was higher in the VTD group, averaging 93% compared to 70% in the VRD one. The incidence of grade 3 or 4 hematological AEs was 31% for VTD and 33% for VRD. The rates of grade 3 or 4 infection-related AEs were 9% in the VTD group and 14% in the VRD one. The incidence of grade 3 or 4 thrombotic AEs was 4% for VTD and 3% for VRD.

CONCLUSIONS:

With comparable safety profiles, VTD and VRD induction therapies are similarly effective for transplant-eligible NDMM, showing similar ORRs and VGPR rates.

1,002

News (Medical) associated with Lenalidomide

20 Nov 2025

·www.pharmaceutical-technology.com

EC authorises Roche’s Lunsumio SC for follicular lymphoma

The therapy demonstrated a high, deep and durable remissions rate and favourable benefit-risk in third-line or later FL. Credit: Kitreel/Shutterstock.com. Roche has received conditional marketing authorisation from the European Commission (EC) for Lunsumio (mosunetuzumab) subcutaneous (SC) for adults with relapsed or refractory follicular lymphoma (R/R FL) after at least two systemic therapies. The approval follows positive results from the Phase I/II GO29781 study, which demonstrated that Lunsumio SC has pharmacokinetic non-inferiority to intravenous (IV) administration. No unexpected safety issues were observed. The SC formulation facilitates outpatient initiation and decreases administration time to around one minute compared to the two-to-four-hour IV infusion process. Lunsumio demonstrated a high deep and durable remissions rate and a favourable benefit-risk profile in third-line or later FL with both IV and SC routes. The IV formulation was the initial bispecific antibody approved for this indication, with 57% of patients achieving a complete remission (CR) which was sustained over five years. Roche chief medical officer and global product development head Levi Garraway stated: “Building on the benefits of its fixed-duration dosing schedule, Lunsumio can now be administered with a one-minute subcutaneous injection, providing people with relapsed or refractory follicular lymphoma an additional treatment option to help meet their individual clinical requirements and lifestyle preferences. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence “Developing new formulations of our medicines is part of our commitment to offering greater flexibility and a better treatment experience for patients.” The company has submitted these outcomes to other healthcare authorities globally, including the US Food and Drug Administration. Phase III trials of Lunsumio SC are underway, including the MorningLyte study investigating the therapy combined with lenalidomide in previously untreated FL patients. Lunsumio is part of Roche’s cluster of differentiation (CD)20xCD3 bispecific antibody portfolio, alongside Columvi (glofitamab). In October 2025, the FDA had granted approval for Roche’s Gazyva/ Gazyvaro (obinutuzumab) to treat adult patients with active lupus nephritis (LN) who were on standard therapy. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Drug ApprovalPhase 3Clinical Result

19 Nov 2025

·firstwordpharma.com

Roche bags EU nod for SC formulation of Lunsumio, re-igniting bispecific battle with Tepkinly

The European Commission granted conditional marketing authorisation to a subcutaneous (SC) formulation of Roche’s Lunsumio (mosunetuzumab) in adults with relapsed or refractory follicular lymphoma (FH) following two or more prior systemic therapies — rekindling the CD20xCD3 bispecific antibody’s rivalry with AbbVie and Genmab's SC bispecific Tepkinly (epcoritamab), cleared last year in the same population.The latest approval introduces an injection alternative to the existing 2-4 hour intravenous infusion version of Lunsumio, originally approved in the EU in 2022."Building on the benefits of its fixed-duration dosing schedule, Lunsumio can now be administered with a one-minute SC injection, providing people…an additional treatment option to help meet their individual clinical requirements and lifestyle preferences," remarked Levi Garraway, Roche's chief medical officer.The EU clearance was supported by results from the Phase I/II GO29781 study, which demonstrated pharmacokinetic non-inferiority of the SC formulation compared with intravenous administration, without any unexpected safety signals. Moreover, in the primary analysis of patients with third-line or later FH, the SC variant achieved a significant objective response rate of 74.5% and a complete response rate of 58.5%, alongside a 20.8-month median duration of complete response.Roche said it has submitted the data also to other regulatory authorities globally, including the FDA. Additionally, long-term data from both SC and intravenous arms of GO29781 will be presented at the American Society of Hematology (ASH) annual meeting next month.The Swiss drugmaker is also running Phase III trials of Lunsumio SC, including MorningLyte, which is evaluating the formulation with Bristol Myers Squibb’s Revlimid (lenalidomide) in previously untreated FL.

Drug ApprovalPhase 3ASHClinical Result

19 Nov 2025

·www.pharmaceutical-technology.com

FDA approves AbbVie’s Epkinly to treat follicular lymphoma

Follicular lymphoma is a slow-growing form of NHL arising from B-lymphocytes. Credit: evan_huang/Shutterstock.com. The US Food and Drug Administration (FDA) has approved AbbVie’s Epkinly (epcoritamab-bysp) to treat adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is for the use of the T-cell engaging bispecific antibody, Epkinly, administered subcutaneously, in combination with rituximab and lenalidomide (Epkinly + R²). It is supported by data from the Phase III Epcore FL-1 study, which assessed the fixed-duration of the combination therapy against the standard treatment of R². The findings highlight the potential to transform treatment strategies for FL, a slow-growing form of non-Hodgkin lymphoma (NHL) arising from B-lymphocytes, affecting 15,000 new patients annually in the US. The Epcore FL-1 trial enrolled a broad patient population, showing that Epkinly in combination with R 2 lowered the risk of disease progression or mortality by 79% comparison to R 2 alone. The overall response rate was 89% for Epkinly + R 2 versus 74% for R 2 . Median progression-free survival was not reached in the Epkinly group versus 11.2 months for R 2 . Complete responses were achieved in 74% of patients receiving Epkinly + R 2 compared to 43% with R 2 . GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence AbbVie oncology, solid tumour and haematology therapeutic area head and vice-president Daejin Abidoye stated: “With this approval, Epkinly is now the first bispecific antibody available for patients with follicular lymphoma in the second-line plus setting. New options are needed to improve outcomes for patients with relapsed or refractory disease.” Epkinly as a single agent received accelerated approval from the FDA in June 2024 to treat R/R FL after two or more lines of systemic therapy. Additional international regulatory submissions are scheduled. In October 2025, the FDA approved AbbVie’s supplemental new drug application , updating the indication statement for Rinvoq (upadacitinib) to treat inflammatory bowel disease. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Phase 3Drug ApprovalClinical ResultAccelerated Approval

100 Deals associated with Lenalidomide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04687	Lenalidomide	L04AX04	DB00480

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Large B-cell lymphoma	United States	Seagen, Inc.	11 Feb 2025
Marginal Zone B-Cell Lymphoma	United States	Bristol Myers Squibb Co.	28 May 2019
Adult T-Cell Leukemia-Lymphoma	Japan	Bristol-Myers Squibb KK	02 Mar 2017
Chromosome 5q Deletion Syndrome	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Chromosome 5q Deletion Syndrome	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Follicular Lymphoma	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Mantle-Cell Lymphoma	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	European Union	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Iceland	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Transfusion dependent anaemia	Norway	Bristol-Myers Squibb Pharma EEIG	14 Jun 2007
Multiple Myeloma	United States	Bristol Myers Squibb Co.	29 Jun 2006

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	United States	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Japan	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Argentina	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Australia	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Austria	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Canada	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Colombia	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Czechia	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	France	Incyte Corp.	11 May 2021
T-cell/histiocyte rich large B-cell lymphoma	Phase 3	Germany	Incyte Corp.	11 May 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01316523 (CTgov)	Phase 2	Indolent Non-Hodgkin Lymphoma	30	Lenalidomide+Rituximab	qiptsadcfe = cdoxwgjhhv frqrnbdwys (vcxlvodplb, uoiehkkchy - zvybulgrug) View more	-	21 Nov 2025
NCT02937571 (CTgov)	Phase 1/2	Multiple Myeloma \| Plasma Cell Leukemia \| Bone Marrow Neoplasms	29	Carfilzomib (Dose Level 1: Carfilzomib 45mg/m2/Dose)	pvsyovhnmk = yeqzjalgug rdeutabtnn (fjbblcatln, umghlmlphn - cvnvrpmqjc) View more	-	20 Nov 2025
				Carfilzomib (Dose Level 2: Carfilzomib 56mg/m2/Dose)	pvsyovhnmk = slvwncgmdj rdeutabtnn (fjbblcatln, skfiqwyhkr - cyyxsxmsgt) View more
NCT05200312 (Pubmed \| BMC Med)	Phase 2	Diffuse Large B-Cell Lymphoma First line	34	Zanubrutinib, lenalidomide, and R-CHOP (ZR2-CHOP)	ycwhpdauol(mphtmnzawr) = Grade 3-4 adverse events occurred in 67.6% of patients, primarily hematologic toxicities jbxqqkvmjg (ezbfudmspy )	Positive	24 Oct 2025
NCT03703167 (Pubmed \| Neuro Oncol)	Phase 1	Primary Central Nervous System Lymphoma	25	Ibrutinib 560mg	nesqddtadj(gmwthpbvvv) = No aspergillosis observed ydqxwmudcy (bivbglryqe ) View more	Positive	17 Sep 2025
NCT02969837 (CTgov)	Phase 2	Multiple Myeloma	46	Lenalidomide+Elotuzumab+carfilzomib+Dexamethasone	clpyidwzjl = gtojvwvgoq bmyzogxugc (yyqgffkpgj, mgoqauqgyf - lybhcthuss) View more	-	10 Sep 2025
NCT05626322 (CTgov)	Phase 1/2	Diffuse Large B-Cell Lymphoma \| Diffuse large B-cell lymphoma recurrent	6	Lenalidomide+Tafasitamab+PF-07901801 (PF-07901801 4 mg/kg + Tafasitamab + Lenalidomide)	cttdbijzqa = dkiklmcaoz yjlhujcslg (wtdrkrlsqe, rkltqygjuy - dsvvkmodry) View more	-	05 Sep 2025
				Lenalidomide+Tafasitamab+PF-07901801 (PF-07901801 10 mg/kg + Tafasitamab + Lenalidomide)	cttdbijzqa = jzbdwygcie yjlhujcslg (wtdrkrlsqe, qluymuhyys - xmkqukphpu) View more
NCT01351896 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	49	Bone Marrow Biopsy+Lenalidomide+Pneumococcal Polyvalent Vaccine (Arm A (Concurrent PCV13 and Lenalidomide))	isdzitvuqd = fxekeminsk zswotzurri (ghgzjfjhqd, lvoscgdaui - tbdyglskna) View more	-	22 Aug 2025
				Bone Marrow Biopsy+Lenalidomide+Pneumococcal Polyvalent Vaccine (Arm B (Sequential PCV13 and Lenalidomide))	isdzitvuqd = safkpntsrj zswotzurri (ghgzjfjhqd, xyohgvbxdp - zbqrxypuvk) View more
NCT05222555 (MINDway, CTgov)	Phase 1/2	Diffuse large B-cell lymphoma recurrent	53	Lenalidomide+Tafasitamab (Tafasitamab Dose Level 1 + 25 mg Lenalidomide)	uvqytpebyq = gqptcvjyqz kjcnbbrwao (rzybigxqgf, xlalmcxrkl - uxyjmxdmxk) View more	-	28 Jul 2025
				Lenalidomide+Tafasitamab (Tafasitamab Dose Level 2 + 25 mg Lenalidomide)	uvqytpebyq = dujxjigrll kjcnbbrwao (rzybigxqgf, yrcvqptzvl - gamchwlqtf) View more
NCT02765854 (CTgov)	Phase 2	Recurrent Multiple Myeloma \| Refractory Multiple Myeloma	70	Ixazomib+Dexamethasone (Arm B (Ixazomib and Dexamethasone))	uecibpoyfe = dwmthzafam xnjyobhmir (qdpyksfhoq, qfqyytmizl - fmksprymzc) View more	-	26 Jun 2025
				Lenalidomide+Ixazomib+Dexamethasone (Arm C (Ixazomib, Dexamethasone, Lenalidomide))	uecibpoyfe = lgrimyvztf xnjyobhmir (qdpyksfhoq, eewoayfpkf - yegkzrwwww) View more
NCT01995669 (CTgov)	Phase 1/2	Marginal zone lymphoma recurrent \| Refractory Follicular Lymphoma \| Refractory Marginal Zone Lymphoma ... View more	66	Obinutuzimab+Lenolidomide (All Participants)	ccxdvtcswh = yqprhpjqkn bebcokhzan (lhgbfrvpcs, gkosgpfhsy - ibmxgoejgd)	-	24 Jun 2025
				Obin (Ph. II: Expansion Len 20 mg Plus Obin 1000 mg)	tohdbeccou(qtyoypatqo) = xqtpvllpwr mouxxpbuys (ibjrgzfmrw, plmslxyiqd - mfeonbcgqg) View more